Stryker Corporation $SYK Shares Purchased by Swedbank AB

Posted by Brenda Bartman on May 25th, 2026

Swedbank AB increased its stake in shares of Stryker Corporation (NYSE:SYK – Free Report) by 6.6% during the 4th quarter, HoldingsChannel.com reports. The fund owned 129,027 shares of the medical technology company’s stock after purchasing an additional 7,934 shares during the period. Swedbank AB’s holdings in Stryker were worth $45,349,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of SYK. Brighton Jones LLC lifted its position in Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after acquiring an additional 609 shares in the last quarter. Schnieders Capital Management LLC. acquired a new position in Stryker during the 2nd quarter worth approximately $205,000. Marshall Wace LLP lifted its position in Stryker by 107.9% during the 2nd quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock worth $2,255,000 after acquiring an additional 77,831 shares in the last quarter. Nebula Research & Development LLC acquired a new position in Stryker during the 2nd quarter worth approximately $219,000. Finally, HUB Investment Partners LLC acquired a new position in Stryker during the 2nd quarter worth approximately $253,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Stryker

In other news, VP M Kathryn Fink sold 3,500 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $283.45, for a total value of $992,075.00. Following the completion of the sale, the vice president directly owned 177 shares in the company, valued at approximately $50,170.65. The trade was a 95.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 4.60% of the company’s stock.

Stryker Stock Performance

Shares of SYK opened at $316.39 on Monday. The business’s 50 day moving average is $325.22 and its two-hundred day moving average is $349.76. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $404.87. The firm has a market cap of $121.29 billion, a price-to-earnings ratio of 36.62, a PEG ratio of 1.99 and a beta of 0.80. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK – Get Free Report) last announced its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. During the same period in the previous year, the company earned $2.84 earnings per share. The business’s revenue for the quarter was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Analysts forecast that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s payout ratio is 40.74%.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Barclays reduced their price target on Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research report on Monday, May 4th. Wall Street Zen lowered Stryker from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. BTIG Research reduced their price target on Stryker from $397.00 to $379.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Truist Financial reissued a “hold” rating and set a $330.00 price target (down from $380.00) on shares of Stryker in a research report on Monday, May 4th. Finally, TD Cowen lowered Stryker from a “buy” rating to a “hold” rating and set a $387.00 target price on the stock. in a research report on Monday, January 26th. Sixteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $395.48.

Check Out Our Latest Stock Report on SYK

Stryker Profile

(Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.